Dr. Jason Hsu discusses the review of patients with PDR who were lost to followup after limited anti-VEGF or PRP treatment and returned for treatment after at least 6 mo.

Full reference:

Obeid, A., Su, D., Patel, S. N., Uhr, J. H., Borkar, D., Gao, X., . . . Hsu, J. (2018). Outcomes of Eyes Lost to Follow-up with Proliferative Diabetic Retinopathy That Received Panretinal Photocoagulation versus Intravitreal Anti-Vascular Endothelial Growth Factor. Ophthalmology. doi:10.1016/j.ophtha.2018.07.027

Drs. Muni and Hillier discuss the results of the PIVOT study that prospectively compared results of pneumatic retinopexy vs. pars plana vitrectomy for repair of rhegmatogenous retinal detachment.

This podcast episode is simulcast with the online appearance of the article.

Full reference:

Hillier, R. J., Felfeli, T., Berger, A. R., Wong, D. T., Altomare, F., Dai, D., . . . Muni, R. H. (2018). The Pneumatic Retinopexy versus Vitrectomy for the Management of Primary Rhegmatogenous Retinal Detachment Outcomes Randomized Trial (PIVOT). Ophthalmology. doi:10.1016/j.ophtha.2018.11.014

Professor Robyn Guymer from Melbourne, Australia discusses results of the LEAD trial that investigated the use of nanopulase laser for dry AMD.

Full reference of the article:

Guymer, R. H., Wu, Z., Hodgson, L. A. B., Caruso, E., Brassington, K. H., Tindill, N., . . . Laser Intervention in Early Stages of Age-Related Macular Degeneration Study, G. (2018). Subthreshold Nanosecond Laser Intervention in Age-Related Macular Degeneration: The LEAD Randomized Controlled Clinical Trial. Ophthalmology. doi:10.1016/j.ophtha.2018.09.015

Dr. Ozkok describes his publication on the association of Red Blood Cells Distribution Width (RDW) and vision in patients with Central or Branch Retina Vein Occlusion.

Full Reference of the article:

Ozkok, A., Nesmith, B. L. W., & Schaal, S. (2018). Association of Red Cell Distribution Width Values with Vision Potential in Retinal Vein Occlusion. Ophthalmology Retina, 2(6), 582-586. doi:10.1016/j.oret.2017.09.018

Dr. Jennifer Sun discusses 5-year results of DRCR.net Protocol S that investigated outcomes of treatment of proliferative diabetic retinopathy using traditional PRP laser vs intravitreal ranibizumab injections.

Full reference:

Gross, J. G., Glassman, A. R., Liu, D., Sun, J. K., Antoszyk, A. N., Baker, C. W., . . . Diabetic Retinopathy Clinical Research, N. (2018). Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA Ophthalmol. doi:10.1001/jamaophthalmol.2018.3255

Please leave your comments in iTunes or send them to [email protected]

Dr. Camiel Boon from Leiden University Medical Center (LUMC) and Amsterdam University Medical Centers in Amsterdam discusses the results of his research work on the comparison of half-dose PDT vs micropulse laser to treat central serous chorioretinopathy.

Full reference of the discussed article:

van Dijk, E. H. C., Fauser, S., Breukink, M. B., Blanco-Garavito, R., Groenewoud, J. M. M., Keunen, J. E. E., . . . Boon, C. J. F. (2018). Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial. Ophthalmology. doi:10.1016/j.ophtha.2018.04.021

Dr. Chakravarthy from Belfast, UK discusses a secondary analysis of the IVAN Trial to compare effects of intravitreal anti-VEGF therapy on serum VEGF levels with possible trends in system adverse events in the context of wet AMD.

Full reference:

Chris A.Rogers, Lauren J.Scott, Barnaby C.Reeves, Susan Downes, Andrew J.Lotery, Andrew D.Dick, Usha Chakravarthy for IVAN trial investigators, Serum Vascular Endothelial Growth Factor Levels in the IVAN Trial; Relationships with Drug, Dosing, and Systemic Serious Adverse Events, Ophthalmology Retina, Feb. 2018

http://dx.doi.org/10.1016/j.oret.2017.05.015

Dr. Charles Wykoff discusses results of DRCR protocol T ancillary study on plasma free VEGF concentrations after different intravitreal anti-VEGF injections for diabetic macular edema.

Full reference of the discussed article:

Jampol, L. M., A. R. Glassman, D. Liu, L. P. Aiello, N. M. Bressler, E. J. Duh, S. Quaggin, et al. "Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema." Ophthalmology (Mar 7 2018).

Dr. Sean Adrean discusses his retrospective analysis of patients with wet AMD who had over 50 anti-VEGF injections.

Full reference of the discussed article:

Adrean, S. D., S. Chaili, H. Ramkumar, A. Pirouz, and S. Grant. "Consistent Long-Term Therapy of Neovascular Age-Related Macular Degeneration Managed by 50 or More Anti-Vegf Injections Using a Treat-Extend-Stop Protocol." Ophthalmology (Feb 10 2018).

Dr. Mark Humayun discusses the results of his team's work on implantation of RPE stems cells placed on a bioengineered surface for dry AMD.

Full reference of the article:

Kashani, A. H., Lebkowski, J. S., Rahhal, F. M., Avery, R. L., Salehi-Had, H., Dang, W., . . . Humayun, M. S. (2018). A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration. Sci Transl Med, 10(435). doi:10.1126/scitranslmed.aao4097